CHEMOPROPHYLAXIS OF TUBERCULOSIS - WHEN IS BENEFIT WORTH RISK AND COST

被引：38

作者：

MOULDING, T

机构：

来源：

关键词：

D O I：

10.7326/0003-4819-74-5-761

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：761 / +

页数：1

共 56 条

[1]

ALARCONSEGOVIA D, 1969, CLIN EXP IMMUNOL, V5, P429

[2]

ALARCONSEGOVIA D, 1969, MAYO CLIN PROC, V44, P664

[3]

ALLISON J, 1961, PNEUMOCONIOSIS MODER, P132

[4]

[Anonymous], 1967, AM REV RESPIR DIS, V96, P558

BICKERS, JN ;

HOOD, BJ ;

ALVAREZC.G ;

BUECHNER, HA .

[6]

BOUCOT KR, 1952, AM REV TUBERC PULM, V65, P1

[7]

CANNAT A, 1966, LANCET, V1, P185

[8] FATAL HEPATIC NECROSIS SECONDARY TO ISONIAZID THERAPY [J].

COHEN, R ;

KALSER, MH ;

THOMSON, RV .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 176 (10) :877-&

[9] RISK OF REACTIVATION [J].

COMSTOCK, GW .

[10]

COMSTOCK GW, 1964, B WORLD HEALTH ORGAN, V31, P161